SNO - Society for Neuro-Oncology - Annual Scientific Meeting

San Francisco, CA, United States, November 16 – November 19, 2017
RSVP for Event / Log Back in

Additional menu options can be found in the menu bar on the left or at the top.

Tocagen Inc. [TOCA] US$126 MM MCap
Can­cer-se­lec­tive gene ther­a­py com­pany. Lead pro­gram To­ca 511 and To­ca FC are be­ing studied in a reg­is­tra­tio­n­al Ph 2/3 trial for re­cur­rent high grade glio­ma (rHGG). A Ph 1 study of To­ca 511 and To­ca FC showed a near dou­bling of sur­vi­val ver­sus his­tor­i­cal bench­marks with durable PRs and CRs. [more in­for­ma­tion]

Event Contact

Clayton Robertson
Solebury Trout